PhenoPath Laboratories
- Company typePrivate
- Founded1998
- HeadquartersSeattle, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
PhenoPath Laboratories firmographics
Firmographics- Name
- PhenoPath Laboratories
- Legal name
- PhenoPath, PLLC
- Website
- https://phenopath.com
- Company type
- Private
- Founded year
- 1998
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Where PhenoPath Laboratories is headquartered
LocationHeadquarters
- HQ city
- Seattle
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
PhenoPath Laboratories business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure
Revenue model
- Clinical Laboratory Testing Services: PhenoPath provides diagnostic testing services to physicians, hospitals, and clinics. Healthcare providers submit specimens for specialized pathology testing including IHC, FISH, flow cytometry, PCR, and cytogenetics. Services are billed using CPT codes and typically reimbursed through insurance or direct client billing arrangements with healthcare institutions.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
PhenoPath Laboratories product offering
Product offeringCore offering
PhenoPath is a physician-owned specialty pathology reference laboratory that provides cancer diagnostic testing services to physicians, hospitals, and biopharmaceutical companies. The lab offers comprehensive anatomic and molecular pathology testing including immunohistochemistry (IHC), 10-color flow cytometry, fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), cytogenetics, immunofluorescence, special stains, and next-generation sequencing, supported by one-on-one pathologist consultations.
Product overview
PhenoPath Laboratories is a physician-owned diagnostic pathology laboratory specializing in cancer diagnostics. The company offers a unified portfolio of specialized testing services centered on anatomical and molecular pathology for cancer diagnosis, treatment planning, and prognosis. Their core offerings include immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), flow cytometry (10-color), polymerase chain reaction (PCR), cytogenetics, immunofluorescence, special stains, and next-generation sequencing. The test menu is organized by disease state and methodology, covering hematologic malignancies (leukemias, lymphomas), solid tumors (breast, lung, colon, prostate, brain/CNS, and others), and molecular biomarkers. PhenoPath operates as part of the Quest Diagnostics network, providing reference pathology testing with academic and medical excellence as the foundation. Services include specialized PD-L1 interpretation and optimization/validation services for biomarker discovery, drug development, and clinical trial applications.
Differentiator
Problem solved
Functional benefit
Products and services
- PD-L1 Interpretation Services
Quantifiable outcome
- HER2 IHC positive predictive value for FISH amplification: 94%
- +1 more outcomes
Companies that use PhenoPath Laboratories
Customer profileSegments3 records
Ideal customer profiles3 records
PhenoPath Laboratories technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
PhenoPath Laboratories partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Quest DiagnosticscorePhenoPath operates as part of the Quest Diagnostics network, providing specialized pathology services through Quest's broader laboratory infrastructure. PhenoPath's BioPharma Services page links directly to Quest Diagnostics' life sciences division, indicating a coordinated approach to serving pharmaceutical and biotech clients with specialized testing needs.
Scale indicators3 records
Recent moves6 records
Expansion highlights6 records
PhenoPath Laboratories competitors and assessment
Company assessmentBroad incumbents
- Sonic Healthcare USA: International reference lab operator with US anatomic pathology and specialty testing capabilities (via subsidiaries such as Aurora Diagnostics). Comparable in offering specialty pathology services to hospitals and referring physicians.
- ARUP Laboratories: Academic-affiliated national reference laboratory offering extensive anatomic pathology, hematopathology, molecular, and specialty oncology testing. Comparable in subspecialty depth and serving complex hospital cases.
- Laboratory Corporation of America (LabCorp): National reference laboratory offering a full menu of clinical and anatomic pathology including IHC, FISH, flow, and molecular oncology testing. Competes with PhenoPath on community oncology and hospital outreach with much broader commercial scale.
- Exact Sciences: Diagnostic company offering molecular oncology tests (Oncotype DX, Cologuard) and broader precision oncology services. Overlaps with PhenoPath in molecular diagnostic and biomarker-driven oncology decision support.
- Cleveland Clinic Laboratories / Mayo Clinic Laboratories: Hospital-based reference laboratories offering esoteric anatomic pathology, hematopathology, molecular oncology, and consult services. Compete with PhenoPath for complex cancer case referrals and second-opinion consultations.
Direct peers
- Foundation Medicine (Roche): Comprehensive genomic profiling services for solid tumors and hematologic malignancies using NGS-based assays. Competes with PhenoPath's molecular and NGS testing, particularly for oncology profiling and biopharma companion diagnostic work.
- Caris Life Sciences: Molecular profiling and biomarker testing company focused on oncology with IHC, FISH, NGS, and companion diagnostic services for oncologists and biopharma. Directly comparable in serving cancer diagnostic decision-making with multi-modality assays.
- NeoGenomics: Specialty oncology reference laboratory offering IHC, FISH, flow cytometry, molecular, and NGS services to oncologists, hospitals, and biopharma clients. Closest direct competitor given overlapping oncology pathology test menu and similar hospital/community oncologist customer base.
Emerging players
- Guardant Health: Liquid biopsy and genomic profiling company offering blood-based cancer diagnostics across solid tumors. Adjacent competitor that pressures traditional tissue-based IHC/FISH reflex testing with non-invasive alternatives.
- Tempus Labs: AI-enabled precision medicine company offering NGS, IHC, and molecular profiling for oncology, including biopharma clinical trial services. Comparable in multi-modality oncology testing and biopharma channel exposure.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
PhenoPath Laboratories social profiles
Digital presencePhenoPath Laboratories financial estimates
Financial estimateRevenue estimate
Valuation estimate
PhenoPath Laboratories leadership team
Management profileNumber of profiles
PhenoPath Laboratories funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PhenoPath Laboratories M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PhenoPath Laboratories
What does PhenoPath Laboratories do?
PhenoPath is a physician-owned specialty pathology reference laboratory that provides cancer diagnostic testing services to physicians, hospitals, and biopharmaceutical companies. The lab offers comprehensive anatomic and molecular pathology testing including immunohistochemistry (IHC), 10-color flow cytometry, fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), cytogenetics, immunofluorescence, special stains, and next-generation sequencing, supported by one-on-one pathologist consultations.
Is PhenoPath Laboratories a public or private company?
PhenoPath Laboratories is a private company. It is classified as corporate owned and is currently operating.
When was PhenoPath Laboratories founded?
PhenoPath Laboratories was founded in 1998. It employs 51 to 100 people.
Where is PhenoPath Laboratories based?
PhenoPath Laboratories is headquartered in Seattle, United States, in the North America region.
How does PhenoPath Laboratories make money?
One revenue line is on record: clinical Laboratory Testing Services.
Who are PhenoPath Laboratories's main competitors?
Broad incumbents on record are Sonic Healthcare USA, ARUP Laboratories, Laboratory Corporation of America (LabCorp), Exact Sciences and Cleveland Clinic Laboratories / Mayo Clinic Laboratories. Direct peers are Foundation Medicine (Roche), Caris Life Sciences and NeoGenomics. Emerging players are Guardant Health and Tempus Labs.
Does PhenoPath Laboratories have an API?
No public API is recorded for PhenoPath Laboratories.